SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Global premature death targets missed
Fri Sept 21st - Most of the world's nations – including the UK, USA and China – are likely to fall short of the United Nations target for reducing the number of premature deaths from non-communicable diseases (NCDs), according to a report out today. More
Genetic mutation link to dangerous fungal spores risk
Fri Sept 21st - A genetic mutation in humans has been discovered that is linked to a 17-fold increase in the number of dangerous fungal spores in the lungs. More
RECENT COMMENTS
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

Media blamed for diverting cash to ineffective drugs

Friday September 14th, 2018

A multi-million pound cancer drugs fund was over-hyped in the media, leading to NHS cash being diverted from effective care, experts say today.

“Mostly positive” stories in newspapers led to the 2010-2015 government continuing the Cancer Drugs Fund in spite of “mounting evidence” of its ineffectiveness, according to the report in the Journal of the Royal Society of Medicine.

Dr Charlotte Chamberlain, a palliative care specialist, said: “By uncritically reporting the assumed benefit of increased access to anti-cancer drugs we do our patients a disservice.

“The price of the hype for pharmaceuticals in the treatment of cancer may cost patients in a number of ways: through potential side effects, by offering false hope without meaningful clinical benefit and preventing investigation of, and investment in, other treatment approaches.

“In an era of alternative facts, journalists, health professionals and cancer charities have a responsibility to interrogate claims of the next big thing.”

The Fund was set up to tackle perceptions that the National Institute for Health and Care Excellence was too slow to evaluate new cancer treatments.

It gave clinicians access to unapproved treatments – but was eventually handed to NICE to manage as costs spiralled out of control.

Biometrician Dr Grant Lewison, of King’s College, London, said there was three times as much coverage in nine popular newspapers in favour of the Fund than against it.

The researchers say that charities should have done more to publicise the failings in the fund.

Dr Lewison said: “Media reports did not scrutinise the discrepancy between those drugs available through the CDF and those diseases with the greatest health burden, the toxicities of the medicines, nor the opportunity cost of the CDF for other cancer treatments.

“Access at any cost was a clear totem around which the pro-CDF media based its coverage.

“The views of experts who pointed out the intrinsic unfairness of the CDF or the lack of efficacy of, and unpleasant side effects from, many of the drugs seem to have counted for little against the human interest stories of individual patients.”

Cancer care and propaganda: UK newspaper reporting of the Cancer Drugs Fund JRSM 14 September 2018; doi: 10.1177/0141076818796802

http://journals.sagepub.com/doi/full/10.1177/0141076818796802

Tags: Cancer | NHS | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES